Purpose Interest in leveraging real-world evidence (RWE) to support regulatory decision
making for product effectiveness has been increasing globally as evident by the increasing …

Real-world evidence (RWE) is increasingly involved in the early benefit assessment of
medicinal drugs. It is expected that RWE will help to speed up approval processes …

Abstract Purpose Real-World Data (RWD) studies are increasingly used to support
regulatory approvals, reimbursement decisions, and changes in clinical practice for novel …

The available evidence on relative effectiveness and risks of new health technologies is
often limited at the time of health technology assessment (HTA). Additionally, a wide variety …

Challenges of health systems in Latin America and the Caribbean include accessibility,
inequity, segmentation, and poverty. These challenges are similar in different countries of …

This research explores the integration of Artificial Intelligence (AI) and Big Data into public
health campaigns, envisioning a future where precision, personalization, and proactive …

Regulators are faced with many challenges surrounding health data usage, including
privacy, fragmentation, validity, and generalizability, especially in the European Union, for …

Real-world evidence (RWE) is being increasingly used by a wide range of stakeholders
involved in the therapeutic product lifecycle but remains underutilized in the health …

Objective: This review aimed to assess the current use and acceptance of real-world data
(RWD) and real-world evidence (RWE) in health technology assessment (HTA) process. It …

Real-world evidence (RWE) can provide insights into patient profiles, disease detection,
treatment choice, dosing strategies, treatment sequencing, adverse event management and …